Research from the University of Minnesota found «strong preclinical evidence for silymarin's hepatoprotective and anticarcinogenic effects.» (mindbodygreen.com)
Osimertinib showed preclinical evidence of concentrations in mouse brain tissue 5 - to 25-fold higher than in plasma, [16] and has shown greater penetration of the BBB in mouse models than gefitinib, rociletinib, or afatinib. (cancernetwork.com)
«Preclinical evidence suggests that dietary interventions, such as calorie restriction, intermittent fasting, low - fat diet and the ketogenic diet, have the potential to reverse some of these obesity - associated alterations; however, more clinical data are needed to confirm translation to human subjects.» (sciencedaily.com)